Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Anticonvulsant or Benzodiazepine or NDRI

Use the filters below to narrow your results.

generic:
brand:
None (9) · Aptiom (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Dalmane (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Doral (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Focalin, Focalin XR (1) · Fycompa (1) · Gabitril (1) · Halcion (1) · Lexotan (1) · Librium (1) · Luminal (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Rohypnol (1) · Sabril (1) · Serax (1) · Tranxene (1) · Versed (1) · Vimpat (1) · Xanax (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
AMPA receptor antagonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1)
uses:
None (40) · ADHD, narcolepsy (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1)
starting dose:
None (42) · 0.25 mg (1)
preparations:
None (42) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1)
fda max:
None (42) · 10 mg/d (1)
routes:
None (40) · Oral (3) · transdermal (1)
onset:
None (40) · 20–60 min (oral) (1) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–60 min (1)
duration:
None (40) · 6 h (immediate-release); ~11 h (extended-release) (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 8–12 h (1)
halflife:
None (40) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1)
bioavailability:
None (40) · 80-90% oral (1) · ~22–25% (1) · ~30% (high first-pass) (1)
pregnancy:
None (40) · Category C (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)
legal:
None (40) · Schedule II (2) · Schedule IV (US) (1)

Showing below up to 44 results in range #1 to #44.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"